IL2 and renal cell carcinoma: Patients with renal cell carcinoma or melanoma who received IT treatment with either recombinant IL-2 or IL-2 encoding plasmids suffered from less toxicity (compared to systemic administration) and promising anti-tumor efficacy was observed.